Loading...
Back to narrative

ASTERDM: Upcoming Board Decisions And ESOP Plan Will Drive Bullish Outlook

Analysts Raise Aster DM Healthcare Price Target as Profit Margins Improve and Valuation Increases

ASTERDM logo
ASTERDM
AnalystConsensusTarget
Not Invested
Published 09 Feb 2025

Update shared on 09 Dec 2025

Previous
n/a
n/a
AnalystConsensusTarget's Fair Value
n/a
Loading
1Y
29.2%
7D
-2.3%

Analysts have maintained their price target on Aster DM Healthcare at ₹777.44 per share, reflecting continued confidence in the company’s robust revenue growth outlook, stable profit margins, and supportive future earnings multiple.

What's in the News

  • Board to meet on November 6, 2025 at 10:30 IST to review unaudited standalone and consolidated financial results for the quarter and half year ended September 30, 2025 (company filing)
  • Board to consider adoption of Aster DM Healthcare Limited Employee Stock Option Scheme 2025, signaling continued focus on long term employee incentives (company filing)
  • Proposal to approve a new registered office premises in the State of Hyderabad, indicating an administrative and potential strategic relocation (company filing)
  • Board to review changes in the composition of its committees as part of broader governance updates (company filing)
  • Resignation of Non Executive Director Anoop Moopen (DIN:02301362) to be taken up at the meeting, which may alter board dynamics (company filing)

Valuation Changes

  • Fair Value: Unchanged at approximately ₹777.44 per share, indicating no revision to the intrinsic value estimate.
  • Discount Rate: Stable at about 12.76 percent, suggesting no change in the perceived risk profile or required return.
  • Revenue Growth: Effectively unchanged at around 53.08 percent, with only an immaterial rounding adjustment.
  • Net Profit Margin: Remains steady at roughly 14.34 percent, reflecting no meaningful change in margin expectations.
  • Future P/E: Holds constant at about 28.81 times, signaling a consistent view of Aster DM Healthcare’s forward earnings multiple.

Have other thoughts on Aster DM Healthcare?

Create your own narrative on this stock, and estimate its Fair Value using our Valuator tool.

Create Narrative

Disclaimer

AnalystConsensusTarget is a tool utilizing a Large Language Model (LLM) that ingests data on consensus price targets, forecasted revenue and earnings figures, as well as the transcripts of earnings calls to produce qualitative analysis. The narratives produced by AnalystConsensusTarget are general in nature and are based solely on analyst data and publicly-available material published by the respective companies. These scenarios are not indicative of the company's future performance and are exploratory in nature. Simply Wall St has no position in the company(s) mentioned. Simply Wall St may provide the securities issuer or related entities with website advertising services for a fee, on an arm's length basis. These relationships have no impact on the way we conduct our business, the content we host, or how our content is served to users. The price targets and estimates used are consensus data, and do not constitute a recommendation to buy or sell any stock, and they do not take account of your objectives, or your financial situation. Note that AnalystConsensusTarget's analysis may not factor in the latest price-sensitive company announcements or qualitative material.